Biotech Startups

Tabula Bio uses machine learning to design in-context DNA algorithms that can outpace microbial evolution and treat infectious disease, positioning itself as an alternative to traditional antibiotic and drug development. The company applies AI to design new DNA faster than pathogens can evolve resistance, and states it is already treating patients.

1 investor

Tabulous is an AI-powered experimental data platform for biotech companies that replaces legacy electronic lab notebooks and laboratory information management systems. The platform enables scientists to collect, organize, and analyze experimental data with minimal onboarding and vendor lock-in.

1 investor

Tacit Machines builds data and compute infrastructure that connects laboratory experiments with large-scale computational analysis. Its systems are intended for biology research groups and biotech organizations that need to move wet-lab data into GPU-based processing pipelines.

1 investor

Tactile Therapeutics is a venture-funded biotechnology company working on Targeted Protein Degradation.

1 investor

Tactiva Therapeutics develops immuno-oncology treatments using adoptive cell therapy approaches for cancer patients. The company leverages innovative methods in T cell engineering and gene therapy to address metastatic and gynecological cancers.

1 investor

TAG Therapeutics develops TELOBLOCK, an antisense nucleotide therapy that inhibits the DNA damage response at short or damaged telomeres to reduce cellular senescence, targeting telomere biology disorders and age-related diseases such as idiopathic pulmonary fibrosis and bone marrow failure. The company also explores ex-vivo applications to improve immune cell fitness for bone marrow transplantation and cancer immunotherapies.

1 investor

The company develops DNA aptamers—single-stranded oligonucleic acid therapeutics—using proprietary artificial base-pair technology for drug discovery and medical applications. The platform aims to create effective and safe pharmaceuticals that can be widely distributed, while also enabling applications in medical devices and diagnostics.

1 investor

Tagomics develops multimodal technologies for precision medicine and next-generation diagnostics. The company is based in Cambridge and focuses on improving patient outcomes through advanced diagnostic technologies.

1 investor

Tailor Bio develops targeted cancer therapies for tumors characterized by chromosomal instability, working in the field of precision oncology.

1 investor

Tait Labs upcycles industrial by-products into health ingredients. The site is currently a placeholder while the company rebuilds its website.

1 investor

Talawar Therapeutics develops bispecific antibodies that combine two disease-driving pathways in a single therapy for greater and more durable treatment effect. Its lead program, TALA-125, is an anti-IL-13 x anti-IL-18 bispecific aimed at first-line patients and those who have failed prior therapies.

1 investor

Tandem Repeat develops Squitex, a biobased fiber material derived from squid ring teeth protein using genetic sequencing tools, intended as an alternative to petroleum-based fibers for the textile industry. The company applies biomimetic design to create durable, more sustainable textile materials.

1 investor

Taninpardaz Pasargad develops cochlear implant systems and hearing-related medical devices and services for deaf and hard-of-hearing patients in Iran.

1 investor

1 investor

TareBio operates a platform for developing personalized and population-level vaccines against cancer and infectious diseases by analyzing immune cells already responding to a disease and reverse-engineering the antigens that activate them. The company works in the biotechnology and vaccine development space.

1 investor

Tarsons manufactures a range of plastic labware products for life sciences research, including bottles, flasks, centrifuge ware, cryo labware, and liquid handling systems. The company serves academic, pharmaceutical, biotechnology, clinical research, and industrial customers across 40+ countries.

1 investor

1 investor

Tasca Therapeutics develops novel cancer therapies using mass spectrometry-based proteomics to identify cancer-causing proteins with auto-palmitoylation modifications, targeting previously unknown binding pockets for difficult-to-treat cancers. The company's lead program, CP-383, is in preclinical development with expected clinical trial entry in 2025.

1 investor

Tattva Bio is developing a biology-driven manufacturing platform that uses photosynthetic biological cells to grow high-performance industrial materials under ambient conditions. The company aims to reduce carbon emissions and resource depletion associated with conventional extractive, energy-intensive material production.

1 investor

TATUM bioscience develops biotech solutions, though the page provides limited detail on specific products or target markets.

1 investor

TauC3 Biologics is a biotechnology company developing therapies for neurodegenerative diseases, with a focus on tau-related and Alzheimer's disease drug discovery. It brings together drug development and neuroscience expertise to advance treatments for CNS disorders.

1 investor

Taudia develops ultrasensitive biomarker detection technology for neurodegenerative disease quantitation, serving researchers, biopharma teams, and clinicians through blood-based diagnostic tools.

1 investor

Tavira Therapeutics develops an AAV delivery platform for gene therapy that uses modular, post-manufacture enzymatic modification of AAV vectors to target intended tissues more accurately. The technology aims to improve delivery efficiency of AAV vector cargo to the right cells and reduce unintended side effects.

1 investor

Tavo Biotherapeutics develops novel treatments for glaucoma and retinal diseases, focusing on disease-modifying therapies that target the root biological mechanisms of vision loss. The company is advancing TAV-001, a topical therapy that modulates the autonomic nervous system to reduce intraocular pressure, improve blood flow to the optic nerve, and provide neuroprotection.

1 investor